NKTR - Nektar Therapeutics

NKTR - Nektar Therapeutics

https://www.nektar.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

NKTR Shares Surge 38.2% in a Week: Here's What You Should Know

Zacks Commentary • 1 week ago • score: 0.18

Nektar shares surge 38.2% on investor optimism on rezpeg's potential in atopic dermatitis after upbeat mid-stage study results.

What's Going On With Nektar Therapeutics Stock On Thursday? - Nektar Therapeutics ( NASDAQ:NKTR )

Benzinga • 1 week, 3 days ago • score: 0.10

Nektar stock trades higher with 2.201 million shares exchanged vs 1.96 million average. Rezpegaldesleukin showed 53%-61% symptom improvement at 16 weeks vs 31% placebo. Get a Year of Fast, Actionable Trade Alerts for 60% Off This Labor Day Nektar Therapeutics Inc.

Nektar Q2 Loss Narrower Than Expected, Revenues Fall Y/Y

Zacks Commentary • 1 month, 1 week ago • score: -0.12

NKTR's second-quarter top and bottom lines beat estimates. Studies on the lead candidate, rezpeg, are progressing well.

Nektar ( NKTR ) Q2 Revenue Falls 52%

Motley Fool • 1 month, 1 week ago • score: 0.14

Nektar Therapeutics ( NASDAQ:NKTR ) , a clinical-stage biopharmaceutical company focusing on immunology and oncology drug development, reported its latest financial results on August 7, 2025, for the second quarter of 2025.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Nektar Therapeutics is a biopharmaceutical company. The company is headquartered in San Francisco, California with additional operations in Huntsville, Alabama and Hyderabad, India.

52W High

$40.45

52W Low

$6.48

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.07

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-6.50

EV/Revenue (<3 favorable)

9.13

P/S (TTM) (<3 favorable)

10.20

P/B (<3 favorable)

2.91

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

0.82%

Institutions (25–75% balanced)

47.42%

Shares Outstanding

19,018,600

Float

17,572,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

74,934,000

Gross Profit (TTM)

62,522,000

EPS (TTM)

-8.64

Profit Margin (>10% good)

-1.63%

Operating Margin (TTM) (higher better)

-3.20%

ROE (TTM) (>15% strong)

-4.41%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-0.52

Momentum

Bearish momentum

Value

7.4891

Previous

7.1060

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025